|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2018||2019||2020||2021||2022||2023E||2024E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services that are used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. Its Life Sciences segment offers a range of instruments and consumables that are used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, and vaccines. Its Diagnostics segment offers clinical instruments, reagents, consumables, software that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease.
- Steven Rales CHM (70)
- Rainer Blair PRE (56)
- Mitchell Rales CFD (64)
- Matthew McGrew CFO (49)
- Jennifer Honeycutt EVP (51)
- Joakim Weidemanis EVP (51)
- Jose-Carlos Gutierrez-Ramos SVP (58)
- Brian Ellis SVP (55)
- Angela Lalor SVP (55)
- William King SVP (53)
- Daniel Raskas SVP (54)
- Christopher Bouda CAO
- Linda Hefner Filler LED (61)
- A. Shane Sanders DRC
- Teri List-Stoll IND (58)
- Walter Lohr IND (77)
- Jessica Mega IND (46)
- Pardis Sabeti IND (45)
- John Schwieters IND (81)
- Alan Spoon IND (69)
- Raymond Stevens IND (57)
- Elias Zerhouni IND (69)
- 2200 Pennsylvania Ave NW Ste 800W, WASHINGTON, 20037-1731
- +1 2028280850
- John Bedford
- Ernst & Young LLP
Latest News for DHR
Upcoming Events for DHR
Danaher Corp at Evercore ISI HealthCONx Conference
Q4 2023 Danaher Corp Earnings Release
Q1 2024 Danaher Corp Earnings Release
Danaher Corp Annual Shareholders Meeting
As of Today at 18:06 UTC, shares in Danaher are trading at $221.41. This share price information is delayed by 15 minutes.
Shares in Danaher last closed at $221.41 and the price had moved by -5.15% over the past 365 days. In terms of relative price strength the Danaher share price has underperformed the S&P500 Index by -16.24% over the past year.
The overall consensus recommendation for Danaher is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Danaher dividend yield is 0.47% based on the trailing twelve month period.
Last year, Danaher paid a total dividend of $1.04, and it currently has a trailing dividend yield of 0.47%. We do not have any data on when Danaher is to next pay dividends.
We do not have data on when Danaher is to next pay dividends. The historic dividend yield on Danaher shares is currently 0.47%.
To buy shares in Danaher you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $221.41, shares in Danaher had a market capitalisation of $163.61bn.
Here are the trading details for Danaher:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: DHR
Based on an overall assessment of its quality, value and momentum Danaher is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Danaher is $235.25. That is 6.25% above the last closing price of $221.41.
Analysts covering Danaher currently have a consensus Earnings Per Share (EPS) forecast of $8.26 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Danaher. Over the past six months, its share price has underperformed the S&P500 Index by -0.78%.
As of the last closing price of $221.41, shares in Danaher were trading +2.68% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Danaher PE ratio based on its reported earnings over the past 12 months is 28.16. The shares last closed at $221.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Danaher's management team is headed by:
- Steven Rales - CHM
- Rainer Blair - PRE
- Mitchell Rales - CFD
- Matthew McGrew - CFO
- Jennifer Honeycutt - EVP
- Joakim Weidemanis - EVP
- Jose-Carlos Gutierrez-Ramos - SVP
- Brian Ellis - SVP
- Angela Lalor - SVP
- William King - SVP
- Daniel Raskas - SVP
- Christopher Bouda - CAO
- Linda Hefner Filler - LED
- A. Shane Sanders - DRC
- Teri List-Stoll - IND
- Walter Lohr - IND
- Jessica Mega - IND
- Pardis Sabeti - IND
- John Schwieters - IND
- Alan Spoon - IND
- Raymond Stevens - IND
- Elias Zerhouni - IND